JADE301 / Jade Biosciences - LARVOL DELTA

Characterization and Development of JADE301, a Half-Life Extended Anti-IFN-β Monoclonal Antibody for Treatment of Dermatomyositis (EADV 2026) - No abstract available

Dermatomyositis • Immunology • Myositis • IFNB1

JADE301: undisclosed antibody program for autoimmune diseases (GlobeNewswire) - "JADE301, an undisclosed antibody program, is expected to enter a first-in-human clinical trial in the first half of 2027. Further details on JADE301 are expected to be disclosed in the second half of 2026."

First-in-human • New molecule • New trial • Immunology